Organisation paid for research Program year 2025 Source: CMS Open Payments

Associated Medical Professionals URO

Neither a doctor nor a teaching hospital

Research payments

$430,392

49 payments

Through program year 2025, Associated Medical Professionals URO is reported as receiving $430,392 in research payments, across 49 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $10,129 1
2024 Research $10,073 1
2023 Research $14,112 2
2022 Research $11,773 3
2021 Research $38,921 3
2020 Research $235,823 26
2019 Research $109,560 13

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $430,392 49 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Subjects with High Risk Non-muscle Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmette-Guerin BCG Therapy $144,635 6 payments
  2. A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Subjects with High Risk Non-muscle Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmette-Guerin BCG Therapy $128,633 10 payments
  3. A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 inSubjects with High Risk Non-muscle Invasive Bladder Cancer NMIBC Unresponsive toBacillus Calmette-Guerin BCG Therapy $86,820 4 payments
  4. A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with Other Investigational Agents in Subjects with High-riskNon-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmette-GuerinBCG Therapy $25,885 5 payments
  5. A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) inSubjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive toBacillus Calmette-Guerin (BCG) Therapy $21,723 1 payment
  6. A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett $10,129 1 payment
  7. A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmette-Guerin BCG Therapy $10,073 1 payment
  8. A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Subjects with High Risk Non-muscle Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmette-Guerin BCG Therapy $1,476 13 payments
  9. A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 inSubjects with High Risk Non-muscle Invasive Bladder Cancer NMIBC Unresponsive toBacillus Calmette-Guerin BCG Therapy $1,017 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record